Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III randomized trial of autologous and allogeneic stem cell transplantation versus intensive conventional chemotherapy in acute lymphoblastic leukemia in first remission.

Next Previous
X
Search
Trial Profile

Phase III randomized trial of autologous and allogeneic stem cell transplantation versus intensive conventional chemotherapy in acute lymphoblastic leukemia in first remission.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Asparaginase; Cetuximab; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Folinic acid; Folinic acid; Imatinib; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms UKALLXII

    • Most Recent Events

    • 22 Nov 2012 Biomarkers information updated
    • 06 Dec 2010 Final results for this trial were presented in an oral presentation at the 52nd American Society o Hematology (ASH), according to an ASH media release.
    • 31 Mar 2010 New source identified and integrated (United Kingdom Clinical Research Network 652).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top